A randomized, double-blind, multiple dose, placebo-controlled study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and efficacy of secukinumab in adult and pediatric patients with new-onset type 1 diabetes mellitus (T1D)
|Effective start/end date||8/17/12 → 3/1/16|
- NOVARTIS PHARMACEUTICALS CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.